Vault Bioventures

02/14/2023

Happy Valentine's Day from the team at Vault Bioventures. Here is to good heart health this and every month!

10/17/2022

09/30/2022

09/27/2022

[T]he U.S. needs to funnel cash toward development of genetic engineering tech, use approaches like artificial intelligence . . . whilst simultaneously breaking down obstacles to commercialization . . ."

The Biden Administration, after setting its sights on America’s pharmaceutical supply chains last winter, is telegraphing its next move to restore the United States' drugmaking prowess. | The Biden Administration, after setting its sights on America’s pharmaceutical supply chains last winter, is...

09/26/2022

What ads made the top of the list for ad spend in August? A couple may surprise you.

AbbVie has taken the top two spots in August’s TV drug ad spenders’ list as it pushes down fierce rival Dupixent into third place, according to real-time ad trackers at iSpot. | AbbVie has taken the top two spots in August’s TV drug ad spenders’ list as it pushes down fierce rival Dupixent i...

09/23/2022

"As it turns out, consumers have no problem watching ads if it means paying less for content."

With a significant shift in the streaming-TV market underway, tracking tech presents an opportunity to get a clearer picture of what consumers care about and how to optimize campaigns targeting them.

09/22/2022

Neurocrine Biosciences is acquiring Diurnal Group, a U.K-based biotech that has commercialized two endocrine disorder drugs. Neurocrine’s top-selling product is a blockbuster drug for an involuntary muscle movement disorder.